Recent Updates
Recently added Catalysts
ORIC

ORIC Pharmaceuticals to Participate in the Guggenheim 2022 Oncology Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will parti
Price reaction · baseline $9.48 (2022-02-01 close) · hit after-hours · clean, no other ORIC news in the window
day 0 close
-6.1%
day 1 · peak
-8.2%
day 3
-3.7%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
10.1%
average across 6 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
ORIC-944
Phase 1 · Metastatic Prostate Cancer

Full Press Release Details

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a virtual fireside chat at the Guggenheim 2022 Oncology Conference on Thursday, February 10, 2022, at 2:00 p.m. ET.
A live webcast of the fireside chat will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
Last updated: Feb 2, 2022